Our library of drug research abstracts drawn from the medical literature is updated on a regular schedule, and you can be assured that new voltaren-ophthalmic research articles will be listed here shortly after becoming available to us.
Related Sponsors
Medical research on voltaren-ophthalmic
Treatment of acute pseudophakic cystoid macular edema: Diclofenac versus ketorolac.
J Cataract Refract Surg. 2003 Dec; 29(12): 2378-84
Rho DS
PURPOSE: To investigate whether topical diclofenac sodium 0.1% solution (Voltaren Ophthalmic) is as efficacious as topical ketorolac tromethamine 0.5% solution (Acular) in the treatment of established, chronic cystoid macular edema (CME) after uneventful phacoemulsification cataract extraction with posterior chamber intraocular lens (IOL) implantation. SETTING: Referral-based vitreoretinal private practice. METHODS: This randomized prospective study comprised 34 consecutive patients with clinical CME after uneventful phacoemulsification cataract extraction with posterior chamber IOL implantation who were referred to a private vitreoretinal practice for evaluation and management. Exclusion criteria included a history of previous intraocular surgery, vitreous loss during cataract surgery, CME, uveitis, and vitreoretinal pathology. The eye with CME was treated with 1 drop 4 times daily of diclofenac sodium 0.1% solution or ketorolac tromethamine 0.5% solution. Outcomes were measured by observing for improvement in CME and visual acuity. RESULTS: Both treatment methods resulted in a significant reduction in CME and a significant improvement in visual acuity. Within 26 weeks, diclofenac reduced CME in 16 patients (89%) and ketorolac, in 14 patients (88%) (P =.92, confidence interval [CI] 95%). Within 26 weeks, diclofenac eliminated CME in 14 patients (78%) and ketorolac, in 12 patients (75%) (P =.86, CI 95%). The mean time to initial CME reduction was 7.5 weeks with diclofenac and 8.0 weeks with ketorolac (P =.41, CI 95%). The mean time to CME resolution was 13.6 weeks with diclofenac and 12.8 weeks with ketorolac (P =.49, CI 95%). CONCLUSIONS: Diclofenac sodium 0.1% solution and ketorolac tromethamine 0.5% topical ophthalmic solution eyedrops were equally effective in reducing the severity and duration of CME after uneventful phacoemulsification with posterior chamber IOL implantation. Either solution may be considered for CME after cataract surgery, especially in patients who may not tolerate corticosteroid treatment.
The effects of topical nonsteroidal anti-inflammatory drugs on adenoviral replication.
Arch Ophthalmol. 1998 Jul; 116(7): 900-5
Gordon YJ, Araullo-Cruz T, Romanowski EG
OBJECTIVE: To evaluate the antiviral activity of topical diclofenac sodium (Voltaren Ophthalmic) and ketorolac tromethamine (Acular) (2 nonsteroidal anti-inflammatory drugs [NSAIDs]) on adenoviral replication in vitro and in the adenovirus (Ad) 5 McEwen-New Zealand rabbit ocular model. METHODS: The 50% inhibitory concentration of ketorolac and diclofenac and their respective preservative components were determined for common ocular adenoviral serotypes (Ad8, Ad19, Ad1, and Ad5). In a series of experiments, Ad5 McEwen-inoculated New Zealand rabbit eyes were treated topically 4 times daily for 18 days with either ketorolac, diclofenac, prednisolone acetate (Pred Forte), or control vehicle (Comfort Tears). MAIN OUTCOME MEASURES: Outcome measures included serial ocular tear film titers and the formation of subepithelial immune corneal infiltrates. RESULTS: In vitro, neither ketorolac nor diclofenac demonstrated significant inhibitory activity against Ad1, Ad5, Ad8, or Ad19. In the rabbit model, there were no statistically significant differences among ketorolac, diclofenac, and the control vehicle with respect to viral replication or the formation of subepithelial immune infiltrates. In contrast, 1% prednisolone prolonged viral shedding and inhibited immune infiltrates (P < .001 for both). CONCLUSIONS: Our experimental study suggests that treatment of epidemic keratoconjunctivitis with topical NSAIDs may be a safer alternative than topical steroids. Only controlled clinical trials can determine whether topical NSAIDs can provide symptomatic relief and not interfere with normal viral clearance.
Cornea. 1997 Jul; 16(4): 406-13
Hettinger ME, Gill DJ, Robin JB, Levy RH, Koester J
PURPOSE: Patients frequently have ocular pain, photophobia, foreign-body sensation, and burning/stinging after radial keratotomy. This study was a prospective, randomized, double-masked, multicenter, fellow-eye comparison of diclofenac sodium (Voltaren Ophthalmic, 0.1% solution) and placebo for controlling these ocular symptoms after bilateral radial keratotomy. METHODS: Patients who were pain free in both eyes before surgery were randomly assigned to treatment with diclofenac sodium in one eye and placebo in the other. One drop of each masked trial medication was administered 30-60 min before surgery, 5 min and 6 h after surgery, at bedtime on the day of surgery, and four times daily for 2 additional days. Patients evaluated ocular symptoms in each eye 0.5, 1, 2, 4, 6, 24, and 48 h after surgery and provided a global evaluation 6, 24, and 48 h after surgery. For each assessment, the difference in scores between eyes was analyzed by using a paired t test. RESULTS: Diclofenac sodium was significantly (p < 0.001) superior to placebo in controlling each ocular symptom at each interval after surgery and for patient global assessments 6, 24, and 48 h after surgery. CONCLUSION: Diclofenac sodium 0.1% ophthalmic solution is clinically effective in controlling adverse ocular symptoms occurring after bilateral radial keratotomy.
Effect of diclofenac on corneal haze after photorefractive keratectomy in rabbits.
Ophthalmology. 1995 Mar; 102(3): 469-74
Nassaralla BA, Szerenyi K, Wang XW, al Reaves T, McDonnell PJ
PURPOSE: To evaluate the ability of topical diclofenac to decrease corneal opacity after excimer laser photorefractive keratectomy (PRK). METHODS: Twenty New Zealand white rabbits underwent a unilateral 193-nm excimer laser myopic photorefractive keratectomy to correct 5 diopters. There were four groups of five rabbits each. The first group of rabbits received postoperative topical treatment with placebo (Voltaren Ophthalmic vehicle), the second group received topical 0.1% diclofenac, the third group received topical corticosteroid (0.1% fluorometholone), and the fourth group received diclofenac and fluorometholone. In the first month, the topical drugs were applied four times daily, and in the second month twice daily. Corneal haze was graded from 0 (totally clear) to 4 (completely opaque cornea). Slit-lamp pictures were obtained at weeks 2, 4, and 8, and keratometry readings was performed at weeks 4 and 8. At week 8, the rabbits were killed, and the eyes were submitted for histologic examination. RESULTS: At week 8, there was less corneal haze in the diclofenac-treated animals and in the fluorometholone-treated animals than in the control group, but only in the diclofenac-treated group was the difference statistically significant. Combination treatment with diclofenac and fluorometholone did not result in a further decrease in haze. CONCLUSIONS: These data suggest that diclofenac and fluorometholone may influence corneal wound healing in rabbits after excimer laser PRK and support a potential role for using topical nonsteroidal anti-inflammatory drugs in preventing the development of excessive corneal haze after excimer laser surgery.
Efficacy of diclofenac sodium solution in reducing discomfort after cataract surgery.
J Cataract Refract Surg. 1995 Mar; 21(2): 187-90
Fry LL
Two hundred consecutive patients were enrolled in a randomized, prospective clinical trial evaluating the efficacy of diclofenac sodium (Voltaren Ophthalmic) in reducing patient discomfort after cataract surgery. Other factors evaluated were the effect of preoperative flurbiprofen (Ocufen) in preventing intraoperative miosis and on postoperative discomfort and the effect of incision size and intraocular carbachol (Miostat) on postoperative comfort. Diclofenac significantly reduced discomfort during the first 24 hours after surgery but not two to three days postoperatively, although there was a trend toward reduction. Flurbiprofen given preoperatively did not affect postoperative discomfort. It also did not affect pupil size at the start of surgery but did reduce intraoperative miosis. Incision size (5.2 mm versus 7.0 mm) had no effect on discomfort. Miostat did not affect discomfort, although there was a trend toward more discomfort. The results indicate that topical diclofenac, given immediately after cataract surgery, significantly reduces discomfort during the first 24 postoperative hours.
J Cataract Refract Surg. 1994 Mar; 20(2): 138-44
Kraff MC, Martin RG, Neumann AC, Weinstein AJ
One hundred forty-eight patients were enrolled in a randomized, prospective, placebo-controlled clinical trial evaluating the efficacy of diclofenac sodium (Voltaren Ophthalmic) in reducing ocular inflammation following extracapsular cataract extraction with posterior chamber intraocular lens implantation. Eligible patients were enrolled and randomized (2:1 diclofenac:placebo) if the sum of anterior chamber cells plus flare one day postoperatively (baseline) was at least four. None of the patients received concomitant steroidal anti-inflammatory treatment. The 99 patients receiving diclofenac sodium had significantly greater improvement from baseline in summed flare plus cell score than the 49 placebo patients at two to five days and seven to nine days after baseline. Similarly, diclofenac sodium patients had significantly less post-baseline conjunctival erythema and ciliary flush than placebo patients. Significantly more diclofenac sodium patients than placebo patients showed moderate to marked improvement from baseline in overall assessment of inflammatory response. Forty-nine percent of placebo patients but only 17% of diclofenac patients were considered therapeutic failures (P < .001). By five to seven days, 82% of diclofenac sodium patients and 59% of placebo patients had corrected visual acuities of 20/40 or better (P < .001). There were no clinically important differences in mean intraocular pressure at any visit.
Use of topical nonsteroidal anti-inflammatory drugs in excimer laser photorefractive keratectomy.
J Cataract Refract Surg. 1994 Mar; 20 Suppl: 216-22
Arshinoff S, D'Addario D, Sadler C, Bilotta R, Johnson TM
Nonsteroidal anti-inflammatory drugs (NSAIDs) produce potent analgesic, antipyretic, and anti-inflammatory effects. We studied postoperative pain in 97 consecutive patients having photorefractive keratectomy (PRK) by an excimer laser with different topical NSAID protocols. Treatment with topical homatropine hydrobromide, either diclofenac sodium (Voltaren Ophthalmic) or ketorolac tromethamine (Acular), and a soft contact lens was most effective in achieving post-PRK analgesia. We also studied post-PRK myopic regression in 68 consecutive patients and found that flurbiprofen sodium (Ocufen), when added to topical steroid protocols, significantly reduced myopic regression for one year postoperatively more than steroids alone or steroids and diclofenac sodium. Diclofenac, used with topical steroids, had less of an additive effect on myopic regression than did flurbiprofen. Topical NSAIDs are useful adjuncts to PRK therapy, both to eliminate postoperative pain and to control post-PRK myopic regression.
Insight. 1993 Apr; 18(1): 8-9, 11
Brennan KM, Brown RM, Roberts CW
Fifty patients undergoing phacoemulsification with posterior chamber intraocular lens implantation were randomly assigned to receive either diclofenac sodium 0.1% eye drops (Voltaren Ophthalmic, CibaVision Ophthalmics, Duluth, GA) or prednisolone acetate 1.0% eye drops (Pred Forte, Allergan Pharmaceuticals, Irvine, CA) as their postoperative anti-inflammatory medication. The patients were examined one day, one week, and one month after surgery, and their postoperative inflammation was evaluated both by slit lamp assessment of cell and flare, and by objective measurement of cell and flare with the Kowa FC-1000 laser cell and flare meter. At each visit, the level of postoperative inflammation was the same for the two study groups. Thus diclofenac sodium was as effective an anti-inflammatory agent for postoperative inflammation as prednisolone acetate.